gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: LL-BMT1

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            Details:

            The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aflibercept

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 15, 2020

            Details:

            The collaboration will research and develop an extended delivery formulation of aflibercept via the suprachoroidal space.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV vectors gene therapy

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Harvard University

            Deal Size: $2000.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration May 11, 2020

            Details:

            CapsidMap™ enables the design of novel Adeno-Associated Virus (AAV) vectors that significantly improve upon current approaches to gene therapy and expand the scope of accessible diseases.